ArticleInternational urology and nephrology2019
Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3-5 patients with asymptomatic hyperuricemia: a network meta-analysis.Renal failure · 2025Pooled it
- Effects of febuxostat in different doses on uric acid, inflammatory factors of serum and knee articular cavity, endothelin-1, and oxidative stress in patients with a gout-a comparative study.African health sciences · 2024Trial
- Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.Scientific reports · 2023Trial
- Uric Acid and Chronic Kidney Disease.Kidney medicine · 2026Review
- Dynamic Uric Acid Changes and Outcomes in CKD in the African American Study of Kidney Disease and Hypertension.Kidney international reports · 2025Article
- Uric Acid Trajectories and CKD Progression in the African American Study of Kidney Disease and Hypertension.Kidney international reports · 2025Article
- Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New-User Active Comparator Cohort Study.Nephrology (Carlton, Vic.) · 2025Article
- Comparison of the incidence of proteinuria and changes in eGFR among febuxostat and topiroxostat users.Clinical and experimental nephrology · 2025Article
- Article
- Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment.International journal of molecular sciences · 2022Review
- Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis.Applied bionics and biomechanics · 2022Article
- Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.PloS one · 2022Article
- A rare case report of reversible acute kidney injury due to hyperuricemia alone.International urology and nephrology · 2021Article
- From purines to purinergic signalling: molecular functions and human diseases.Signal transduction and targeted therapy · 2021Review
- Renal effects of uric acid: hyperuricemia and hypouricemia.The Korean journal of internal medicine · 2020Review
- Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection.Current hypertension reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to compare efficacy of renal-protective function between febuxostat and allopurinol in patients with chronic kidney disease (CKD) and hyperuricemia (HUA).
methodsTotally 152 CKD stage 2-3 patients complicated with HUA were recruited. According to their uric acid-lowering therapy, there were 67 patients included in febuxostat group and 85 in allopurinol group, respectively. Estimated glomerular filtration rate (eGFR), serum creatinine (Scr), 24-h proteinuria, serum uric acid (SUA) were measured at M0, M1, M3 and M6 after the treatment. Primary outcome was proportion of patients showing ≥ 10% decline in eGFR from baseline at M6.
resultsThe eGFR at M6 was numerically higher at M6 and eGFR change (M6-M0) was increased in febuxostat group compared with allopurinol group. Most importantly, the proportion of patients showing a ≥ 10% decline in eGFR from baseline at M6 was reduced in febuxostat group compared with allopurinol group. Multivariate logistic regression analyses further validated that febuxostat vs. allopurinol was an independent predictor for reduced risk of eGFR decline ≥ 10% from baseline. Besides, SUA change (M6-M0) was decreased, but Scr change (M6-M0) and 24-h proteinuria change (M6-M0) were similar in febuxostat group compared with allopurinol group.
conclusionsFebuxostat presents a superior effect in delaying renal impairment progression compared with allopurinol in CKD patients complicated with HUA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.